Sanofi vaccines unit enters agreement with HHS to increase production capability
Sanofi Pasteur, the vaccines global business unit of Sanofi, has entered into an agreement with the U.S. Department of Health and Human Services, or HHS, to increase the company's domestic pandemic influenza vaccine production capabilities based in Swiftwater, Pennsylvania. The contract is supported by federal funds from the Biomedical Advance Research and Development Authority, or BARDA, part of the Office of the Assistant Secretary for Preparedness and Response at HHS. The contract will support the clinical development and manufacturing of an adjuvanted recombinant pandemic vaccine to help enhance U.S. and global pandemic preparedness. This investigational pandemic vaccine will utilize the same recombinant technology as Sanofi's Flublok Quadrivalent. In addition, the contract will expand the site's role as a center of excellence for pandemic preparedness by adding both recombinant and adjuvant manufacturing alongside current egg-based manufacturing. Flublok Quadrivalent is indicated for adults 18 years of age and older and proven in a randomized controlled trial to help prevent 30%-43% more cases of laboratory-confirmed influenza in people 50 years of age and older compared to a standard-dose quadrivalent inactivated influenza vaccine.